"Introduction: Microsatellite instable (deficient mismatch repair, dMMR) colon cancer is associated with hypermutability and immune infiltration-activation. COVID-19 vaccines stimulate immune-inflammation response. This study aimed to investigate the types and rates of COVID-19 vaccines in patients with newly diagnosed colon cancer and compare it according to the microsatellite status...
Discussion: In this case-control study, we revealed that the mRNA-based COVID-19 vaccine is associated with dMMR non-metastatic colon cancer. The BNT162b2 vaccine is associated with the higher risk of dMMR non-metastatic colon cancer, while CoronaVac is not associated with MSI status. Moreover, patients who received the BNT162b2 vaccine and have dMMR colon cancer had higher levels of CRP and sedimentation and lower levels of lymphocyte/CRP ratio, which suggest an inflammatory and immune relationship between mRNA-based vaccine and dMMR status."
© Copyright 2024. Akkus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.